ERBB2 and breast cancer: TNBC constitutes 15–20% of BC, being clinically characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and the absence of amplification of human epidermal growth factor receptor 2 (HER2), which are the known drivers of other BC types [2].